Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <i>BRAF</i>-Mutant Melanoma.-论文-万方医学网

第一作者： Jean-Pierre,Delord

第一单位： Institut Universitaire du Cancer, Toulouse, France. delord.jean-pierre@iuct-oncopole.fr.

作者： Jean-Pierre,Delord ^[1] ; Caroline,Robert ^[2] ; Marta,Nyakas ^[3] ; Grant A,McArthur ^[4] ; Ragini,Kudchakar ^[5] ; Amit,Mahipal ^[6] ; Yasuhide,Yamada ^[7] ; Ryan,Sullivan ^[8] ; Ana,Arance ^[9] ; Richard F,Kefford ^[10] ; Matteo S,Carlino ^[11] ; Manuel,Hidalgo ^[12] ; Carlos,Gomez-Roca ^[13] ; Daniela,Michel ^[14] ; Abdelkader,Seroutou ^[14] ; Vassilios,Aslanis ^[14] ; Giordano,Caponigro ^[15] ; Darrin D,Stuart ^[15] ; Laure,Moutouh-de Parseval ^[14] ; Tim,Demuth ^[14] ; Reinhard,Dummer ^[16]

作者单位： Institut Universitaire du Cancer, Toulouse, France. delord.jean-pierre@iuct-oncopole.fr. ^[1] Gustave Roussy and Paris-Sud University, Villejuif, France. ^[2] Oslo University Hospital, Norway. ^[3] Peter MacCallum Cancer Centre and the University of Melbourne, Australia. ^[4] Winship Cancer Institute of Emory University, Atlanta, Georgia. ^[5] Lee Moffitt Cancer Center and Research Institute, Tampa, Florida. ^[6] National Cancer Center Hospital, Tokyo, Japan. ^[7] Massachusetts General Hospital, Boston, Massachusetts. ^[8] Department of Medical Oncology and Translational Genomics and Targeted Therapeutics in Solid Tumors, Hospital Clínic, Barcelona, Spain. ^[9] Crown Princess Mary Cancer Centre Westmead Hospital, Melanoma Institute Australia, University of Sydney, Sydney, New South Wales, Australia.;Macquarie University, Sydney, New South Wales, Australia. ^[10] Crown Princess Mary Cancer Centre Westmead Hospital, Melanoma Institute Australia, University of Sydney, Sydney, New South Wales, Australia. ^[11] Spanish National Cancer Research Centre (CNIO) and Centro Integral Oncologico Clara Campal, Madrid, Spain. ^[12] Institut Universitaire du Cancer, Toulouse, France. ^[13] Novartis Pharma AG, Basel, Switzerland. ^[14] Novartis Institutes for Biomedical Research, Cambridge, Massachusetts. ^[15] University Hospital Zurich, Zurich, Switzerland. ^[16]

医学主题词动物(Animals);抗肿瘤药(Antineoplastic Agents);氨甲酸酯类(Carbamates);疾病模型, 动物(Disease Models, Animal);药物评价, 临床前(Drug Evaluation, Preclinical);药物监测(Drug Monitoring);女(雌)性(Female);人类(Humans);Kaplan-Meiers评估(Kaplan-Meier Estimate);男(雄)性(Male);最大耐受剂量(Maximum Tolerated Dose);黑色素瘤(Melanoma);小鼠(Mice);分子靶向治疗(Molecular Targeted Therapy);突变(Mutation);肿瘤分期(Neoplasm Staging);蛋白激酶抑制剂(Protein Kinase Inhibitors);原癌基因蛋白质B-raf(Proto-Oncogene Proteins B-raf);磺胺类(Sulfonamides);治疗结果(Treatment Outcome);异种移植模型抗肿瘤试验(Xenograft Model Antitumor Assays)

DOI 10.1158/1078-0432.CCR-16-2923

PMID 28611198

发布时间 2018-12-12

检索历史清除

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <i>BRAF</i>-Mutant Melanoma.

Clinical cancer research

相似文献

同项目论文

Clinical cancer research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic <i>BRAF</i>-Mutant Melanoma.

Clinical cancer research

相似文献

同项目论文

Clinical cancer research

相关期刊

检索历史清除